Combination therapy for advanced rectal cancer before surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called SHR-1701 combined with standard chemotherapy and radiation for people with locally advanced rectal cancer. The goal is to shrink the tumor before surgery, making it easier to remove completely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have a type of rectal cancer called adenocarcinoma that has spread to nearby tissues or lymph nodes
- Your tumor shows a specific genetic pattern (pMMR or MSS/MSI-L)
- You have not had any prior treatment for this cancer, such as surgery, chemo, or radiation
- You can swallow pills and are in good enough health to undergo treatment (ECOG score 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs (adebrelimab and SHR-8068) to standard chemoradiation before surgery can improve outcomes for adults with locally advanced rectal cancer that can be surgically removed.
This trial studies whether adding SHR-1701 to standard chemotherapy and long-course radiation can improve treatment for locally advanced rectal cancer that can be removed by surgery. It’s mainly for people who have not had prior rectal cancer treatment and who fit several health and cancer-spread requirements.
This trial tests treatments given before surgery for colorectal cancer that has not spread. The goal is to shrink the tumor and improve surgical outcomes. It may be an option for patients with stage II or III colorectal cancer who have not had prior treatment.
This trial tests a combination of two immunotherapy drugs and chemotherapy given before surgery for a type of rectal cancer that has a specific genetic marker (MSI-H/dMMR). The goal is to shrink the tumor and improve the chances of successful surgery.
This trial tests a combination of three new drugs (SHR-1701, SHR2554, and BP102) for people with metastatic colorectal cancer. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a combination of radiation, chemotherapy, and two immunotherapy drugs (sintilimab and suvemcitug) to see if it can improve outcomes for patients with locally advanced rectal cancer that has not spread. The goal is to shrink the tumor before surgery, potentially making it easier to remove and reducing the risk of recurrence.
Hear when a new CRC (Colorectal Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.